| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | disaccharide binding | 1.43e-07 | 7 | 33 | 3 | GO:0048030 | |
| GeneOntologyMolecularFunction | galactoside binding | 3.43e-07 | 9 | 33 | 3 | GO:0016936 | |
| GeneOntologyMolecularFunction | oligosaccharide binding | 4.60e-06 | 20 | 33 | 3 | GO:0070492 | |
| GeneOntologyMolecularFunction | protein serine/threonine kinase activator activity | 2.88e-04 | 78 | 33 | 3 | GO:0043539 | |
| GeneOntologyMolecularFunction | ephrin receptor activity | 4.45e-04 | 19 | 33 | 2 | GO:0005003 | |
| GeneOntologyMolecularFunction | single-stranded DNA helicase activity | 6.56e-04 | 23 | 33 | 2 | GO:0017116 | |
| GeneOntologyMolecularFunction | carbohydrate binding | 1.63e-03 | 310 | 33 | 4 | GO:0030246 | |
| GeneOntologyMolecularFunction | fibronectin binding | 1.79e-03 | 38 | 33 | 2 | GO:0001968 | |
| GeneOntologyMolecularFunction | protein kinase activator activity | 1.89e-03 | 149 | 33 | 3 | GO:0030295 | |
| GeneOntologyMolecularFunction | kinase activator activity | 2.27e-03 | 159 | 33 | 3 | GO:0019209 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell degranulation | 1.49e-08 | 4 | 33 | 3 | GO:0043322 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell degranulation | 2.08e-07 | 8 | 33 | 3 | GO:0043321 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell activation | 1.68e-06 | 15 | 33 | 3 | GO:0032815 | |
| GeneOntologyBiologicalProcess | negative regulation of CD4-positive, alpha-beta T cell proliferation | 1.68e-06 | 15 | 33 | 3 | GO:2000562 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte degranulation | 2.50e-06 | 17 | 33 | 3 | GO:0043301 | |
| GeneOntologyBiologicalProcess | natural killer cell degranulation | 3.00e-06 | 18 | 33 | 3 | GO:0043320 | |
| GeneOntologyBiologicalProcess | negative regulation of alpha-beta T cell proliferation | 3.55e-06 | 19 | 33 | 3 | GO:0046642 | |
| GeneOntologyBiologicalProcess | positive regulation of defense response to bacterium | 3.55e-06 | 19 | 33 | 3 | GO:1900426 | |
| GeneOntologyBiologicalProcess | regulation of T cell chemotaxis | 4.18e-06 | 20 | 33 | 3 | GO:0010819 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell differentiation | 4.87e-06 | 21 | 33 | 3 | GO:0032823 | |
| GeneOntologyBiologicalProcess | regulation of defense response to bacterium | 9.46e-06 | 26 | 33 | 3 | GO:1900424 | |
| GeneOntologyBiologicalProcess | regulation of CD4-positive, alpha-beta T cell proliferation | 1.19e-05 | 28 | 33 | 3 | GO:2000561 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell proliferation | 1.47e-05 | 30 | 33 | 3 | GO:0035739 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte chemotaxis | 1.63e-05 | 31 | 33 | 3 | GO:1901623 | |
| GeneOntologyBiologicalProcess | positive regulation of regulatory T cell differentiation | 1.63e-05 | 31 | 33 | 3 | GO:0045591 | |
| GeneOntologyBiologicalProcess | negative regulation of regulated secretory pathway | 1.79e-05 | 32 | 33 | 3 | GO:1903306 | |
| GeneOntologyBiologicalProcess | T cell chemotaxis | 1.97e-05 | 33 | 33 | 3 | GO:0010818 | |
| GeneOntologyBiologicalProcess | regulation of T cell differentiation in thymus | 2.79e-05 | 37 | 33 | 3 | GO:0033081 | |
| GeneOntologyBiologicalProcess | natural killer cell differentiation | 3.03e-05 | 38 | 33 | 3 | GO:0001779 | |
| GeneOntologyBiologicalProcess | positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway | 3.31e-05 | 115 | 33 | 4 | GO:0090100 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 3.54e-05 | 40 | 33 | 3 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of CD4-positive, alpha-beta T cell activation | 3.54e-05 | 40 | 33 | 3 | GO:2000515 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell migration | 3.82e-05 | 41 | 33 | 3 | GO:2000406 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 3.82e-05 | 41 | 33 | 3 | GO:0002716 | |
| GeneOntologyBiologicalProcess | natural killer cell activation involved in immune response | 4.10e-05 | 42 | 33 | 3 | GO:0002323 | |
| GeneOntologyBiologicalProcess | positive regulation of macrophage activation | 4.10e-05 | 42 | 33 | 3 | GO:0043032 | |
| GeneOntologyBiologicalProcess | positive regulation of SMAD protein signal transduction | 4.41e-05 | 43 | 33 | 3 | GO:0060391 | |
| GeneOntologyBiologicalProcess | negative regulation of exocytosis | 5.06e-05 | 45 | 33 | 3 | GO:0045920 | |
| GeneOntologyBiologicalProcess | positive regulation of oxidoreductase activity | 5.40e-05 | 46 | 33 | 3 | GO:0051353 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated cytotoxicity | 5.77e-05 | 47 | 33 | 3 | GO:0001911 | |
| GeneOntologyBiologicalProcess | regulation of T-helper 17 type immune response | 5.77e-05 | 47 | 33 | 3 | GO:2000316 | |
| GeneOntologyBiologicalProcess | positive regulation of interleukin-10 production | 6.14e-05 | 48 | 33 | 3 | GO:0032733 | |
| GeneOntologyBiologicalProcess | positive regulation of lymphocyte migration | 6.54e-05 | 49 | 33 | 3 | GO:2000403 | |
| GeneOntologyBiologicalProcess | regulation of regulatory T cell differentiation | 6.54e-05 | 49 | 33 | 3 | GO:0045589 | |
| GeneOntologyBiologicalProcess | negative regulation of type II interferon production | 7.37e-05 | 51 | 33 | 3 | GO:0032689 | |
| GeneOntologyBiologicalProcess | negative regulation of cell killing | 7.82e-05 | 52 | 33 | 3 | GO:0031342 | |
| GeneOntologyBiologicalProcess | negative regulation of alpha-beta T cell activation | 7.82e-05 | 52 | 33 | 3 | GO:0046636 | |
| GeneOntologyBiologicalProcess | lymphocyte chemotaxis | 8.28e-05 | 53 | 33 | 3 | GO:0048247 | |
| GeneOntologyBiologicalProcess | regulation of alpha-beta T cell proliferation | 8.28e-05 | 53 | 33 | 3 | GO:0046640 | |
| GeneOntologyBiologicalProcess | ephrin receptor signaling pathway | 8.75e-05 | 54 | 33 | 3 | GO:0048013 | |
| GeneOntologyBiologicalProcess | regulatory T cell differentiation | 8.75e-05 | 54 | 33 | 3 | GO:0045066 | |
| GeneOntologyBiologicalProcess | regulation of T cell migration | 9.76e-05 | 56 | 33 | 3 | GO:2000404 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell proliferation | 1.14e-04 | 59 | 33 | 3 | GO:0046633 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell activation | 1.26e-04 | 61 | 33 | 3 | GO:0032814 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte degranulation | 1.39e-04 | 63 | 33 | 3 | GO:0043300 | |
| GeneOntologyBiologicalProcess | heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules | 1.39e-04 | 63 | 33 | 3 | GO:0007157 | |
| GeneOntologyBiologicalProcess | T-helper 17 type immune response | 1.45e-04 | 64 | 33 | 3 | GO:0072538 | |
| GeneOntologyBiologicalProcess | type II interferon production | 1.48e-04 | 169 | 33 | 4 | GO:0032609 | |
| GeneOntologyBiologicalProcess | regulation of interleukin-10 production | 2.24e-04 | 74 | 33 | 3 | GO:0032653 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated cytotoxicity | 2.42e-04 | 76 | 33 | 3 | GO:0042269 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte migration | 2.52e-04 | 77 | 33 | 3 | GO:2000401 | |
| GeneOntologyBiologicalProcess | interleukin-10 production | 2.52e-04 | 77 | 33 | 3 | GO:0032613 | |
| GeneOntologyBiologicalProcess | telomere maintenance via recombination | 2.57e-04 | 15 | 33 | 2 | GO:0000722 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell mediated immunity | 2.82e-04 | 80 | 33 | 3 | GO:0002715 | |
| GeneOntologyBiologicalProcess | T cell migration | 2.92e-04 | 81 | 33 | 3 | GO:0072678 | |
| GeneOntologyBiologicalProcess | regulation of macrophage activation | 2.92e-04 | 81 | 33 | 3 | GO:0043030 | |
| GeneOntologyBiologicalProcess | negative regulation of cell adhesion | 3.02e-04 | 375 | 33 | 5 | GO:0007162 | |
| GeneOntologyBiologicalProcess | receptor clustering | 3.14e-04 | 83 | 33 | 3 | GO:0043113 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 3.14e-04 | 83 | 33 | 3 | GO:0002707 | |
| GeneOntologyBiologicalProcess | positive regulation of chemokine production | 3.25e-04 | 84 | 33 | 3 | GO:0032722 | |
| GeneOntologyBiologicalProcess | regulation of oxidoreductase activity | 3.25e-04 | 84 | 33 | 3 | GO:0051341 | |
| GeneOntologyBiologicalProcess | positive regulation of interleukin-1 production | 3.73e-04 | 88 | 33 | 3 | GO:0032732 | |
| GeneOntologyBiologicalProcess | anatomical structure formation involved in morphogenesis | 3.98e-04 | 1483 | 33 | 9 | GO:0048646 | |
| GeneOntologyBiologicalProcess | regulation of SMAD protein signal transduction | 3.99e-04 | 90 | 33 | 3 | GO:0060390 | |
| GeneOntologyBiologicalProcess | cellular response to virus | 3.99e-04 | 90 | 33 | 3 | GO:0098586 | |
| GeneOntologyBiologicalProcess | skeletal muscle tissue development | 4.26e-04 | 223 | 33 | 4 | GO:0007519 | |
| GeneOntologyBiologicalProcess | enzyme-linked receptor protein signaling pathway | 4.46e-04 | 1186 | 33 | 8 | GO:0007167 | |
| GeneOntologyBiologicalProcess | alpha-beta T cell activation | 4.55e-04 | 227 | 33 | 4 | GO:0046631 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 4.82e-04 | 96 | 33 | 3 | GO:0002704 | |
| GeneOntologyBiologicalProcess | regulation of CD4-positive, alpha-beta T cell activation | 5.43e-04 | 100 | 33 | 3 | GO:2000514 | |
| GeneOntologyBiologicalProcess | regulation of cell adhesion | 5.54e-04 | 927 | 33 | 7 | GO:0030155 | |
| GeneOntologyBiologicalProcess | skeletal muscle organ development | 5.61e-04 | 240 | 33 | 4 | GO:0060538 | |
| GeneOntologyBiologicalProcess | muscle organ development | 6.01e-04 | 436 | 33 | 5 | GO:0007517 | |
| GeneOntologyBiologicalProcess | positive regulation of mononuclear cell migration | 6.09e-04 | 104 | 33 | 3 | GO:0071677 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated cytotoxicity | 6.26e-04 | 105 | 33 | 3 | GO:0042267 | |
| GeneOntologyBiologicalProcess | female pregnancy | 6.44e-04 | 249 | 33 | 4 | GO:0007565 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell proliferation | 6.61e-04 | 107 | 33 | 3 | GO:0042130 | |
| GeneOntologyBiologicalProcess | lymphocyte activation involved in immune response | 6.64e-04 | 251 | 33 | 4 | GO:0002285 | |
| GeneOntologyBiologicalProcess | leukocyte degranulation | 6.79e-04 | 108 | 33 | 3 | GO:0043299 | |
| GeneOntologyBiologicalProcess | chromosome organization | 6.81e-04 | 686 | 33 | 6 | GO:0051276 | |
| GeneOntologyBiologicalProcess | natural killer cell mediated immunity | 6.98e-04 | 109 | 33 | 3 | GO:0002228 | |
| GeneOntologyBiologicalProcess | SMAD protein signal transduction | 7.17e-04 | 110 | 33 | 3 | GO:0060395 | |
| GeneOntologyBiologicalProcess | mononuclear cell migration | 7.36e-04 | 258 | 33 | 4 | GO:0071674 | |
| GeneOntologyBiologicalProcess | maintenance of protein location | 7.55e-04 | 112 | 33 | 3 | GO:0045185 | |
| GeneOntologyBiologicalProcess | negative regulation of innate immune response | 7.95e-04 | 114 | 33 | 3 | GO:0045824 | |
| GeneOntologyBiologicalProcess | T cell differentiation in thymus | 7.95e-04 | 114 | 33 | 3 | GO:0033077 | |
| GeneOntologyBiologicalProcess | leukocyte chemotaxis | 8.36e-04 | 267 | 33 | 4 | GO:0030595 | |
| GeneOntologyBiologicalProcess | lymphocyte migration | 8.36e-04 | 116 | 33 | 3 | GO:0072676 | |
| GeneOntologyBiologicalProcess | mitotic recombination | 8.50e-04 | 27 | 33 | 2 | GO:0006312 | |
| GeneOntologyBiologicalProcess | positive regulation of interleukin-6 production | 9.68e-04 | 122 | 33 | 3 | GO:0032755 | |
| GeneOntologyBiologicalProcess | natural killer cell activation | 1.01e-03 | 124 | 33 | 3 | GO:0030101 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte proliferation | 1.01e-03 | 124 | 33 | 3 | GO:0050672 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte mediated cytotoxicity | 1.01e-03 | 124 | 33 | 3 | GO:0001910 | |
| GeneOntologyBiologicalProcess | positive regulation of catalytic activity | 1.02e-03 | 1028 | 33 | 7 | GO:0043085 | |
| GeneOntologyBiologicalProcess | regulation of chemokine production | 1.04e-03 | 125 | 33 | 3 | GO:0032642 | |
| GeneOntologyBiologicalProcess | negative regulation of mononuclear cell proliferation | 1.06e-03 | 126 | 33 | 3 | GO:0032945 | |
| GeneOntologyBiologicalProcess | multi-organism reproductive process | 1.14e-03 | 290 | 33 | 4 | GO:0044703 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell activation | 1.14e-03 | 290 | 33 | 4 | GO:0050870 | |
| GeneOntologyBiologicalProcess | multi-multicellular organism process | 1.19e-03 | 294 | 33 | 4 | GO:0044706 | |
| GeneOntologyBiologicalProcess | positive regulation of tumor necrosis factor production | 1.24e-03 | 133 | 33 | 3 | GO:0032760 | |
| GeneOntologyCellularComponent | collagen-containing extracellular matrix | 1.92e-05 | 530 | 34 | 7 | GO:0062023 | |
| GeneOntologyCellularComponent | extracellular matrix | 7.46e-05 | 656 | 34 | 7 | GO:0031012 | |
| GeneOntologyCellularComponent | external encapsulating structure | 7.60e-05 | 658 | 34 | 7 | GO:0030312 | |
| GeneOntologyCellularComponent | lysosomal lumen | 5.38e-04 | 98 | 34 | 3 | GO:0043202 | |
| GeneOntologyCellularComponent | microtubule end | 1.74e-03 | 38 | 34 | 2 | GO:1990752 | |
| GeneOntologyCellularComponent | cell cortex region | 2.43e-03 | 45 | 34 | 2 | GO:0099738 | |
| GeneOntologyCellularComponent | chromosome, telomeric region | 2.90e-03 | 176 | 34 | 3 | GO:0000781 | |
| GeneOntologyCellularComponent | vacuolar lumen | 2.99e-03 | 178 | 34 | 3 | GO:0005775 | |
| MousePheno | enhanced humoral immune response | 6.58e-06 | 17 | 31 | 3 | MP:0020155 | |
| MousePheno | increased T-helper 1 cell number | 9.34e-06 | 19 | 31 | 3 | MP:0008086 | |
| MousePheno | increased spleen germinal center size | 1.70e-05 | 23 | 31 | 3 | MP:0008483 | |
| MousePheno | abnormal lymph node germinal center morphology | 1.70e-05 | 23 | 31 | 3 | MP:0008522 | |
| MousePheno | abnormal T-helper 1 cell number | 1.94e-05 | 24 | 31 | 3 | MP:0008085 | |
| MousePheno | abnormal lymph node secondary follicle morphology | 2.20e-05 | 25 | 31 | 3 | MP:0002346 | |
| MousePheno | lymph node hyperplasia | 5.15e-05 | 33 | 31 | 3 | MP:0008102 | |
| MousePheno | thymus hyperplasia | 5.64e-05 | 34 | 31 | 3 | MP:0000708 | |
| MousePheno | increased susceptibility to induced arthritis | 6.71e-05 | 36 | 31 | 3 | MP:0003724 | |
| MousePheno | autoimmune arthritis | 9.03e-05 | 108 | 31 | 4 | MP:0002993 | |
| MousePheno | abnormal lymph node B cell domain morphology | 1.23e-04 | 44 | 31 | 3 | MP:0002344 | |
| MousePheno | abnormal T-helper 1 cell morphology | 1.60e-04 | 48 | 31 | 3 | MP:0002433 | |
| MousePheno | abnormal lymph node cortex morphology | 1.80e-04 | 50 | 31 | 3 | MP:0002343 | |
| MousePheno | joint inflammation | 1.90e-04 | 131 | 31 | 4 | MP:0002933 | |
| MousePheno | increased T-helper cell number | 2.53e-04 | 56 | 31 | 3 | MP:0013763 | |
| MousePheno | abnormal joint physiology | 2.81e-04 | 145 | 31 | 4 | MP:0031169 | |
| MousePheno | increased susceptibility to autoimmune disorder | 3.62e-04 | 155 | 31 | 4 | MP:0005350 | |
| MousePheno | decreased regulatory T cell number | 3.75e-04 | 64 | 31 | 3 | MP:0004974 | |
| MousePheno | abnormal skeleton physiology | 3.80e-04 | 632 | 31 | 7 | MP:0001533 | |
| MousePheno | increased B cell proliferation | 5.99e-04 | 75 | 31 | 3 | MP:0005154 | |
| MousePheno | abnormal Peyer's patch morphology | 8.05e-04 | 83 | 31 | 3 | MP:0000696 | |
| MousePheno | abnormal gut-associated lymphoid tissue morphology | 8.62e-04 | 85 | 31 | 3 | MP:0002378 | |
| MousePheno | spleen hyperplasia | 8.62e-04 | 85 | 31 | 3 | MP:0000693 | |
| Domain | Gal-bind_lectin | 2.25e-06 | 15 | 33 | 3 | SM00908 | |
| Domain | GALECTIN | 2.25e-06 | 15 | 33 | 3 | PS51304 | |
| Domain | Galectin_CRD | 2.25e-06 | 15 | 33 | 3 | IPR001079 | |
| Domain | Gal-bind_lectin | 2.25e-06 | 15 | 33 | 3 | PF00337 | |
| Domain | GLECT | 2.25e-06 | 15 | 33 | 3 | SM00276 | |
| Domain | - | 2.30e-05 | 95 | 33 | 4 | 2.60.120.200 | |
| Domain | RECEPTOR_TYR_KIN_V_2 | 2.72e-04 | 14 | 33 | 2 | PS00791 | |
| Domain | RECEPTOR_TYR_KIN_V_1 | 2.72e-04 | 14 | 33 | 2 | PS00790 | |
| Domain | EphA2_TM | 2.72e-04 | 14 | 33 | 2 | PF14575 | |
| Domain | Tyr_kinase_ephrin_rcpt | 2.72e-04 | 14 | 33 | 2 | IPR016257 | |
| Domain | Eph_TM | 2.72e-04 | 14 | 33 | 2 | IPR027936 | |
| Domain | Ephrin_rcpt_lig-bd_dom | 2.72e-04 | 14 | 33 | 2 | IPR001090 | |
| Domain | Tyr_kinase_rcpt_V_CS | 2.72e-04 | 14 | 33 | 2 | IPR001426 | |
| Domain | EPH_LBD | 2.72e-04 | 14 | 33 | 2 | PS51550 | |
| Domain | EPH_lbd | 2.72e-04 | 14 | 33 | 2 | SM00615 | |
| Domain | Ephrin_lbd | 2.72e-04 | 14 | 33 | 2 | PF01404 | |
| Domain | ConA-like_dom | 5.76e-04 | 219 | 33 | 4 | IPR013320 | |
| Domain | Ephrin_rec_like | 8.85e-04 | 25 | 33 | 2 | SM01411 | |
| Domain | Tyr-kin_ephrin_A/B_rcpt-like | 8.85e-04 | 25 | 33 | 2 | IPR011641 | |
| Domain | AAA | 3.80e-03 | 52 | 33 | 2 | PF00004 | |
| Domain | ATPase_AAA_core | 4.09e-03 | 54 | 33 | 2 | IPR003959 | |
| Domain | SAM_1 | 6.41e-03 | 68 | 33 | 2 | PF00536 | |
| Domain | - | 7.36e-03 | 73 | 33 | 2 | 2.60.120.260 | |
| Domain | TyrKc | 1.05e-02 | 88 | 33 | 2 | SM00219 | |
| Domain | Tyr_kinase_cat_dom | 1.05e-02 | 88 | 33 | 2 | IPR020635 | |
| Domain | SAM | 1.05e-02 | 88 | 33 | 2 | SM00454 | |
| Domain | EGF-like_CS | 1.08e-02 | 261 | 33 | 3 | IPR013032 | |
| Domain | EGF_2 | 1.13e-02 | 265 | 33 | 3 | PS01186 | |
| Domain | Galactose-bd-like | 1.20e-02 | 94 | 33 | 2 | IPR008979 | |
| Domain | SAM_DOMAIN | 1.22e-02 | 95 | 33 | 2 | PS50105 | |
| Domain | PROTEIN_KINASE_TYR | 1.27e-02 | 97 | 33 | 2 | PS00109 | |
| Domain | SAM | 1.27e-02 | 97 | 33 | 2 | IPR001660 | |
| Pathway | REACTOME_EPH_EPHRIN_MEDIATED_REPULSION_OF_CELLS | 2.20e-05 | 34 | 23 | 3 | MM15025 | |
| Pathway | REACTOME_DEFECTIVE_CHST14_CAUSES_EDS_MUSCULOCONTRACTURAL_TYPE | 7.09e-05 | 8 | 23 | 2 | M27260 | |
| Pathway | REACTOME_DEFECTIVE_CHSY1_CAUSES_TPBS | 7.09e-05 | 8 | 23 | 2 | M27261 | |
| Pathway | REACTOME_DEFECTIVE_CHST3_CAUSES_SEDCJD | 7.09e-05 | 8 | 23 | 2 | M27259 | |
| Pathway | REACTOME_EPH_EPHRIN_MEDIATED_REPULSION_OF_CELLS | 7.51e-05 | 51 | 23 | 3 | M27311 | |
| Pathway | REACTOME_DERMATAN_SULFATE_BIOSYNTHESIS | 1.39e-04 | 11 | 23 | 2 | M27105 | |
| Pathway | REACTOME_EPH_EPHRIN_SIGNALING | 1.55e-04 | 65 | 23 | 3 | MM14911 | |
| Pathway | REACTOME_CS_DS_DEGRADATION | 2.29e-04 | 14 | 23 | 2 | M651 | |
| Pathway | REACTOME_EPH_EPHRIN_SIGNALING | 4.33e-04 | 92 | 23 | 3 | M27201 | |
| Pathway | REACTOME_DEFECTIVE_B4GALT7_CAUSES_EDS_PROGEROID_TYPE | 4.75e-04 | 20 | 23 | 2 | M27258 | |
| Pathway | REACTOME_CHONDROITIN_SULFATE_BIOSYNTHESIS | 4.75e-04 | 20 | 23 | 2 | M658 | |
| Pathway | REACTOME_NERVOUS_SYSTEM_DEVELOPMENT | 7.70e-04 | 261 | 23 | 4 | MM15676 | |
| Pathway | REACTOME_A_TETRASACCHARIDE_LINKER_SEQUENCE_IS_REQUIRED_FOR_GAG_SYNTHESIS | 8.08e-04 | 26 | 23 | 2 | M708 | |
| Pathway | REACTOME_TRANSCRIPTIONAL_REGULATION_OF_PLURIPOTENT_STEM_CELLS | 1.15e-03 | 31 | 23 | 2 | M27393 | |
| Pathway | KEGG_AXON_GUIDANCE | 1.16e-03 | 129 | 23 | 3 | M5539 | |
| Pathway | KEGG_MEDICUS_REFERENCE_HOMOLOGOUS_RECOMBINATION | 1.30e-03 | 33 | 23 | 2 | M47842 | |
| Pathway | PID_ATR_PATHWAY | 1.82e-03 | 39 | 23 | 2 | M46 | |
| Pathway | WP_NEURAL_CREST_CELL_MIGRATION_DURING_DEVELOPMENT | 1.91e-03 | 40 | 23 | 2 | M39798 | |
| Pathway | PID_FOXM1_PATHWAY | 1.91e-03 | 40 | 23 | 2 | M176 | |
| Pathway | REACTOME_DISEASES_ASSOCIATED_WITH_GLYCOSAMINOGLYCAN_METABOLISM | 2.01e-03 | 41 | 23 | 2 | M27257 | |
| Pathway | REACTOME_NERVOUS_SYSTEM_DEVELOPMENT | 2.03e-03 | 575 | 23 | 5 | M29853 | |
| Pathway | WP_NEURAL_CREST_CELL_MIGRATION_IN_CANCER | 2.21e-03 | 43 | 23 | 2 | M39788 | |
| Pathway | REACTOME_HOMOLOGOUS_DNA_PAIRING_AND_STRAND_EXCHANGE | 2.21e-03 | 43 | 23 | 2 | M27588 | |
| Pathway | PID_FANCONI_PATHWAY | 2.63e-03 | 47 | 23 | 2 | M1 | |
| Pathway | REACTOME_EXTENSION_OF_TELOMERES | 2.74e-03 | 48 | 23 | 2 | MM17213 | |
| Pathway | REACTOME_CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM | 2.97e-03 | 50 | 23 | 2 | M678 | |
| Pathway | REACTOME_DISEASES_OF_DNA_REPAIR | 3.09e-03 | 51 | 23 | 2 | M29854 | |
| Pathway | REACTOME_EXTENSION_OF_TELOMERES | 3.09e-03 | 51 | 23 | 2 | M14804 | |
| Pathway | REACTOME_HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM | 3.85e-03 | 57 | 23 | 2 | M692 | |
| Pubmed | Galectin-9 Is Critical for Mucosal Adaptive Immunity through the T Helper 17-IgA Axis. | 8.54e-10 | 3 | 34 | 3 | 29458010 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 19776007 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 26582205 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 9153289 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 33316546 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 18974023 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 9038233 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 23144904 | ||
| Pubmed | Impaired Gal-9 Dysregulates the PBMC-Induced Th1/Th2 Imbalance in Abortion-Prone Matings. | 8.54e-10 | 3 | 34 | 3 | 29651447 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 28704475 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 21146220 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 23836896 | ||
| Pubmed | Sequence and mapping of galectin-5, a beta-galactoside-binding lectin, found in rat erythrocytes. | 8.54e-10 | 3 | 34 | 3 | 7890611 | |
| Pubmed | Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. | 8.54e-10 | 3 | 34 | 3 | 22341088 | |
| Pubmed | Regulation of M1‑type and M2‑type macrophage polarization in RAW264.7 cells by Galectin‑9. | 8.54e-10 | 3 | 34 | 3 | 28990062 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 32380082 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 23667648 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 18579572 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 28877989 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 19800850 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 38987795 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 16990264 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 18005988 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 23585851 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 24477688 | ||
| Pubmed | A unique role for galectin-9 in angiogenesis and inflammatory arthritis. | 8.54e-10 | 3 | 34 | 3 | 29433546 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 37105392 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 36479526 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 23242525 | ||
| Pubmed | Galectin-9 in allergic airway inflammation and hyper-responsiveness in mice. | 8.54e-10 | 3 | 34 | 3 | 19851072 | |
| Pubmed | The Role of Galectin-9 as Mediator of Atopic Dermatitis: Effect on Keratinocytes. | 8.54e-10 | 3 | 34 | 3 | 33923930 | |
| Pubmed | Alarmin function of galectin-9 in murine respiratory tularemia. | 8.54e-10 | 3 | 34 | 3 | 25898318 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 31937306 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 21426359 | ||
| Pubmed | Intracellular Galectin-9 Enhances Proximal TCR Signaling and Potentiates Autoimmune Diseases. | 8.54e-10 | 3 | 34 | 3 | 31969388 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 18282810 | ||
| Pubmed | Obesity-induced galectin-9 is a therapeutic target in B-cell acute lymphoblastic leukemia. | 8.54e-10 | 3 | 34 | 3 | 35241678 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 24083426 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 37279535 | ||
| Pubmed | The protective function of galectin-9 in liver ischemia and reperfusion injury in mice. | 8.54e-10 | 3 | 34 | 3 | 25931247 | |
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 22627368 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 33153471 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 22052881 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 17560833 | ||
| Pubmed | 8.54e-10 | 3 | 34 | 3 | 35643073 | ||
| Pubmed | Galectin-9 functionally impairs natural killer cells in humans and mice. | 8.54e-10 | 3 | 34 | 3 | 23408620 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 38686388 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 22677125 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 19234217 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 35715604 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 19017954 | ||
| Pubmed | Galectin-9 Targets NLRP3 for Autophagic Degradation to Limit Inflammation. | 3.41e-09 | 4 | 34 | 3 | 33963043 | |
| Pubmed | Galectin-9: A novel promoter of atherosclerosis progression. | 3.41e-09 | 4 | 34 | 3 | 36459823 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 33107565 | ||
| Pubmed | Galectin-9 inhibits TLR7-mediated autoimmunity in murine lupus models. | 3.41e-09 | 4 | 34 | 3 | 29611821 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 30763585 | ||
| Pubmed | Lgals9 deficiency ameliorates obesity by modulating redox state of PRDX2. | 3.41e-09 | 4 | 34 | 3 | 33727589 | |
| Pubmed | Tim-3-Galectin-9 pathway involves the suppression induced by CD4+CD25+ regulatory T cells. | 3.41e-09 | 4 | 34 | 3 | 19362679 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 25578313 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 29844236 | ||
| Pubmed | Galectin-9/TIM-3 interaction regulates virus-specific primary and memory CD8 T cell response. | 3.41e-09 | 4 | 34 | 3 | 20463811 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 32855403 | ||
| Pubmed | Galectin-3 mediates oligomerization of secreted hensin using its carbohydrate-recognition domain. | 3.41e-09 | 4 | 34 | 3 | 23657851 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 18826117 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 24333756 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 38853593 | ||
| Pubmed | Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodies. | 3.41e-09 | 4 | 34 | 3 | 24958847 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 30120235 | ||
| Pubmed | [Expression of Galectin-9 and Tim-3 in lungs of mice with asthma]. | 3.41e-09 | 4 | 34 | 3 | 21575348 | |
| Pubmed | Activation of Tim-3-Galectin-9 pathway improves survival of fully allogeneic skin grafts. | 3.41e-09 | 4 | 34 | 3 | 18346632 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 11839756 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 19670381 | ||
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 25450716 | ||
| Pubmed | The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. | 3.41e-09 | 4 | 34 | 3 | 16286920 | |
| Pubmed | Galectin-9 regulates the threshold of B cell activation and autoimmunity. | 3.41e-09 | 4 | 34 | 3 | 34369876 | |
| Pubmed | 3.41e-09 | 4 | 34 | 3 | 33203936 | ||
| Pubmed | Influence of galectin-9/Tim-3 interaction on herpes simplex virus-1 latency. | 3.41e-09 | 4 | 34 | 3 | 22021615 | |
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 29242193 | ||
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 28951537 | ||
| Pubmed | Galectin-9 mediates neutrophil capture and adhesion in a CD44 and β2 integrin-dependent manner. | 8.52e-09 | 5 | 34 | 3 | 34847625 | |
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 22469568 | ||
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 25158758 | ||
| Pubmed | C/EBPzeta (CHOP/Gadd153) is a negative regulator of LPS-induced IL-6 expression in B cells. | 8.52e-09 | 5 | 34 | 3 | 19782405 | |
| Pubmed | Embryonic implantation in galectin 1/galectin 3 double mutant mice. | 8.52e-09 | 5 | 34 | 3 | 9566950 | |
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 26278059 | ||
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 37352334 | ||
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 33664349 | ||
| Pubmed | The glucose transporter 2 regulates CD8+ T cell function via environment sensing. | 8.52e-09 | 5 | 34 | 3 | 37884694 | |
| Pubmed | 8.52e-09 | 5 | 34 | 3 | 21385853 | ||
| Pubmed | 1.31e-08 | 27 | 34 | 4 | 36197846 | ||
| Pubmed | 1.70e-08 | 6 | 34 | 3 | 28394331 | ||
| Pubmed | Tim3 binding to galectin-9 stimulates antimicrobial immunity. | 1.70e-08 | 6 | 34 | 3 | 20937702 | |
| Pubmed | 1.70e-08 | 6 | 34 | 3 | 8674632 | ||
| Pubmed | 1.70e-08 | 6 | 34 | 3 | 23296703 | ||
| Pubmed | Role of galectin-1 in the developing mouse olfactory system. | 2.98e-08 | 7 | 34 | 3 | 8873770 | |
| Pubmed | 4.76e-08 | 8 | 34 | 3 | 23751344 | ||
| Pubmed | 4.76e-08 | 8 | 34 | 3 | 31661141 | ||
| Pubmed | 4.76e-08 | 8 | 34 | 3 | 36883358 | ||
| Pubmed | 7.14e-08 | 9 | 34 | 3 | 21670307 | ||
| Pubmed | Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. | 7.14e-08 | 9 | 34 | 3 | 25065622 | |
| GeneFamily | Galectins | 1.05e-06 | 15 | 25 | 3 | 629 | |
| GeneFamily | Fibronectin type III domain containing|Sterile alpha motif domain containing|EPH receptors | 1.65e-04 | 14 | 25 | 2 | 1095 | |
| GeneFamily | Sterile alpha motif domain containing | 6.53e-03 | 88 | 25 | 2 | 760 | |
| Coexpression | NABA_ECM_AFFILIATED | 1.80e-06 | 158 | 34 | 5 | MM17063 | |
| Coexpression | NABA_ECM_AFFILIATED | 2.59e-06 | 170 | 34 | 5 | M5880 | |
| Coexpression | GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN | 9.44e-06 | 1124 | 34 | 9 | MM1070 | |
| Coexpression | NABA_MATRISOME | 3.46e-05 | 1008 | 34 | 8 | MM17056 | |
| Coexpression | NABA_MATRISOME | 3.93e-05 | 1026 | 34 | 8 | M5889 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HPROGFPM | 8.81e-05 | 354 | 34 | 5 | M39061 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HDA1 | 9.43e-05 | 584 | 34 | 6 | M39068 | |
| Coexpression | GSE42088_UNINF_VS_LEISHMANIA_INF_DC_8H_DN | 1.20e-04 | 197 | 34 | 4 | M9910 | |
| Coexpression | GSE26030_TH1_VS_TH17_RESTIMULATED_DAY15_POST_POLARIZATION_UP | 1.25e-04 | 199 | 34 | 4 | M8580 | |
| Coexpression | GSE6875_TCONV_VS_TREG_DN | 1.25e-04 | 199 | 34 | 4 | M6800 | |
| Coexpression | MAHADEVAN_GIST_MORPHOLOGICAL_SWITCH | 1.70e-04 | 15 | 34 | 2 | M6900 | |
| Coexpression | MORI_MATURE_B_LYMPHOCYTE_DN | 1.71e-04 | 83 | 34 | 3 | MM596 | |
| Coexpression | AFFAR_YY1_TARGETS_UP | 1.74e-04 | 217 | 34 | 4 | MM1156 | |
| Coexpression | BURTON_ADIPOGENESIS_9 | 2.10e-04 | 89 | 34 | 3 | MM1026 | |
| Coexpression | MORI_LARGE_PRE_BII_LYMPHOCYTE_UP | 2.39e-04 | 93 | 34 | 3 | MM1137 | |
| Coexpression | CAIRO_LIVER_DEVELOPMENT_DN | 2.52e-04 | 239 | 34 | 4 | MM1274 | |
| Coexpression | HUMMERICH_SKIN_CANCER_PROGRESSION_UP | 2.96e-04 | 100 | 34 | 3 | MM514 | |
| Coexpression | NABA_MATRISOME_ASSOCIATED | 3.35e-04 | 738 | 34 | 6 | MM17058 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_1000 | 1.33e-05 | 983 | 33 | 9 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_1000 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_500_k-means-cluster#5 | 2.76e-05 | 232 | 33 | 5 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_500_K5 | |
| CoexpressionAtlas | DevelopingKidney_e12.5_renal vesicle_emap-27679_k-means-cluster#4_top-relative-expression-ranked_100 | 6.52e-05 | 8 | 33 | 2 | gudmap_developingKidney_e12.5_renal vesicle_100_k4 | |
| CoexpressionAtlas | gallbladder | 7.92e-05 | 148 | 33 | 4 | gallbladder | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_500 | 9.88e-05 | 493 | 33 | 6 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_500 | |
| CoexpressionAtlas | FacebaseRNAseq_e10.5_Neural Epithelium Overlying Central Eminence_top-relative-expression-ranked_1000 | 1.03e-04 | 986 | 33 | 8 | Facebase_RNAseq_e10.5_Neural Epithelium Overlying Central Eminence_1000 | |
| CoexpressionAtlas | DevelopingKidney_e12.5_renal vesicle_emap-27679_k-means-cluster#3_top-relative-expression-ranked_200 | 1.53e-04 | 12 | 33 | 2 | gudmap_developingKidney_e12.5_renal vesicle_200_k3 | |
| CoexpressionAtlas | DevelopingKidney_e13.5_podocyte cells_emap-27773_k-means-cluster#5_top-relative-expression-ranked_200 | 1.81e-04 | 13 | 33 | 2 | gudmap_developingKidney_e13.5_podocyte cells_200_k5 | |
| CoexpressionAtlas | FacebaseRNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_top-relative-expression-ranked_1000_k-means-cluster#4 | 2.72e-04 | 204 | 33 | 4 | Facebase_RNAseq_ratio_e10.5_MaxillaryArch_vs_Mandibular_1000_K4 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.16e-06 | 169 | 34 | 4 | 16c52a0f6d96ecc1832922fce9b39691849f0d73 | |
| ToppCell | COVID-19_Moderate-NK_CD56bright|COVID-19_Moderate / disease group, cell group and cell class | 8.95e-06 | 173 | 34 | 4 | a07dcb1e555caaa2235aec219334fcbf2d07f10c | |
| ToppCell | Adult-Epithelial-lung_goblet_cell-D231|Adult / Lineage, Cell type, age group and donor | 9.15e-06 | 174 | 34 | 4 | 7d2f802f493f19a068e097b2909a9000e2160266 | |
| ToppCell | PND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.58e-06 | 176 | 34 | 4 | d30241fb8119834d6e7b59efec3f92fc7a3d1247 | |
| ToppCell | Adult-Epithelial-lung_goblet_cell|Adult / Lineage, Cell type, age group and donor | 1.02e-05 | 179 | 34 | 4 | 1fc1f252ca943a2f649d1e627f56acbf15f8e058 | |
| ToppCell | droplet-Lung-21m-Hematologic-myeloid-myeloid_dendritic_cell-Ccr7+_dendritic|21m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.02e-05 | 179 | 34 | 4 | 4f20540bfbcefe0e83812be7ea542e8bb3bf19bc | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-Ccr7+_Dendritic|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.02e-05 | 179 | 34 | 4 | d78eacf47847a50888dd16c35bed9b7afc80010f | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum_-18m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-05 | 180 | 34 | 4 | fa819df81fca95c2cc602fede635cb03e3f35fad | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum_-18m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.05e-05 | 180 | 34 | 4 | 907cd510fd2e21532ce04ba687e8894f7af71f27 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW10-Macroglial|GW10 / Sample Type, Dataset, Time_group, and Cell type. | 1.58e-05 | 200 | 34 | 4 | ef222dc4a205d670172dae74990bdb952ac92e5b | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW10-Macroglial-Astrocyte|GW10 / Sample Type, Dataset, Time_group, and Cell type. | 1.58e-05 | 200 | 34 | 4 | 98a994692440cb4f505b050276f0c8022c814a21 | |
| ToppCell | Fetal_brain-organoid_Tanaka_cellReport-GW12-Macroglial-Glia_progenitor_cell|GW12 / Sample Type, Dataset, Time_group, and Cell type. | 1.58e-05 | 200 | 34 | 4 | 4b937b1d0179d1d0e51931f35720e205d460a07e | |
| ToppCell | PBMC-Mild-Myeloid-Neutrophil-immature_Neutrophil|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 8.72e-05 | 113 | 34 | 3 | b795a0c65114b3c0758fe3720e8a80247f900971 | |
| ToppCell | frontal_cortex-Non-neuronal-oligodendrocyte-Oligo-OPC_Pdgfra_Grm5|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.41e-04 | 133 | 34 | 3 | 63d2f096ae47d9b587acc6c5fbd346e5e58842b8 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-E|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.51e-04 | 136 | 34 | 3 | edfd453c9a650d69d05a5a3ab15f7df56349fa86 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-E-|Fibroblasts / Donor, Lineage, Cell class and subclass (all cells) | 1.51e-04 | 136 | 34 | 3 | 03e4e2353c23ceffde35b2d0aadd15299e3db09f | |
| ToppCell | E16.5-samps-Mesenchymal-Matrix_fibroblast-_fetal-Intermediate_Fibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass | 1.54e-04 | 137 | 34 | 3 | dd5364a1002650d21e0c83d8c701b5f7b09d1c19 | |
| ToppCell | primary_visual_cortex-Non-neuronal-oligodendrocyte-Oligo-OPC_Pdgfra_Grm5|primary_visual_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.61e-04 | 139 | 34 | 3 | a957ea4e581646c76b16b6a7f89579b8c7ac35b6 | |
| ToppCell | Club_cells-Cryobiopsy_01|World / lung cells shred on cell class, cell subclass, sample id | 1.98e-04 | 149 | 34 | 3 | 81c813588bb5efb7b31141a75d387210dcb76094 | |
| ToppCell | 343B-Lymphocytic-NK_cells-NK_cell_D2|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.14e-04 | 153 | 34 | 3 | 0b3b199678d4a70b0590393568c69454bece5c14 | |
| ToppCell | droplet-Fat-SCAT-30m-Myeloid|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.18e-04 | 154 | 34 | 3 | 73de626b210ec5482ba89a65e784c1e77ff2894e | |
| ToppCell | droplet-Fat-SCAT-30m-Myeloid-myeloid_cell|Fat / Fat_BAT_GAT_MAT_SCAT - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.18e-04 | 154 | 34 | 3 | 56fe9953e58f71626d3ddf63d340ed35dfc4ce9f | |
| ToppCell | E15.5-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|E15.5 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.18e-04 | 154 | 34 | 3 | e65e4636646164610f33f7bbac0d879a3ea55986 | |
| ToppCell | URO-Lymphocyte-T_NK-CD4_Naive|URO / Disease, Lineage and Cell Type | 2.18e-04 | 154 | 34 | 3 | 6c214ad5cbbfa8bab3f76b593cb598dfb914b566 | |
| ToppCell | COPD-Epithelial-Aberrant_Basaloid|Epithelial / Disease state, Lineage and Cell class | 2.35e-04 | 158 | 34 | 3 | 8f66979e92f886d86cecbd26aaa0c5915c049734 | |
| ToppCell | P07-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P07 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 2.48e-04 | 161 | 34 | 3 | b19f82dd98a3064581793711bb70373f18abecd9 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_convalescent_d42-56-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c02-NCAM1|Severe-critical_convalescent_d42-56 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.53e-04 | 162 | 34 | 3 | 9b1c07f0af657095379380c39d763cab0ad73e74 | |
| ToppCell | 367C-Lymphocytic-NK_cells-NK_cell_B2|367C / Donor, Lineage, Cell class and subclass (all cells) | 2.53e-04 | 162 | 34 | 3 | 59c0dcb5b51c1803660aeec51b60deceeeaeea66 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.57e-04 | 163 | 34 | 3 | 55fd4f21c7a8bea031fb6f7f2c8cc1ff42b00d79 | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)-Glut_NP_L5/6_FEZF2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.57e-04 | 163 | 34 | 3 | d7057ae155058a13f3d7c3db5c7fbc3bb2b69376 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.71e-04 | 166 | 34 | 3 | c22a97353f7eb084f768c13d7767a80b30f05043 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)-Glut_NP_L5/6_FEZF2|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.71e-04 | 166 | 34 | 3 | 01544c851588f1cde05d6700c3d1167f70a0fbd5 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.76e-04 | 167 | 34 | 3 | 50c29ea660bf07b890e4ac1a1985d0761d863dee | |
| ToppCell | Somatosensory_Cortex_(S1)-Neuronal-Inh_GABAergic-i_Gaba_1-GABA_L1_LAMP5-Inh_L6_LAMP5_C1QL2|Somatosensory_Cortex_(S1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 2.76e-04 | 167 | 34 | 3 | 721a932024d55de7212dc6ec9e4d7f463c2bcda2 | |
| ToppCell | renal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell_cycling-Cycling_Proximal_Tubule_Epithelial_Cell_G2M|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 2.81e-04 | 168 | 34 | 3 | d35944fd9fea9934ce1e76b2b35d48e2300cca61 | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.91e-04 | 170 | 34 | 3 | 5570c0e825bca77613bf0ebde620cf744fa1cb84 | |
| ToppCell | COVID-19_Moderate-NK_CD56bright|World / disease group, cell group and cell class | 2.91e-04 | 170 | 34 | 3 | caa6a534c1e9639caced9a51680f5c905f061bcc | |
| ToppCell | droplet-Lung-nan-21m-Myeloid-dendritic_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.96e-04 | 171 | 34 | 3 | 159ce6d5513008532dd7785b915b3fe7440cc4b2 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.01e-04 | 172 | 34 | 3 | 86f52f486d67217fc1b8443ab362c975df2974a4 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.01e-04 | 172 | 34 | 3 | fb2df8fea6df5947165f13978f1d1006d15b60fd | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_ILC-NK_cell|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.01e-04 | 172 | 34 | 3 | e38ebb216e4ddcd008148fcbaf709b4f3c83706a | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-5w-Mesenchymal-Cilia-bearing_cell|5w / Sample Type, Dataset, Time_group, and Cell type. | 3.06e-04 | 173 | 34 | 3 | d4cbeae262abfa30d8c5452285d3261a96875610 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_C_(NP)-Glut_NP_L5/6_FEZF2-Exc_L5-6_FEZF2_MYBPHL|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 3.06e-04 | 173 | 34 | 3 | b002b22f9968b5967d29fe0eab4e796d87b355fa | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Immune-Myeloid-Macrophage_Dendritic-Cycling_Mononuclear_Phagocyte|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 3.11e-04 | 174 | 34 | 3 | 7b318796728001c17b4043d2b033330c7be40c78 | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Hematopoietic-T_cells-NK_cell|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.17e-04 | 175 | 34 | 3 | d427c1eaea805046b1e4944d374adc7095f710a1 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-24m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.17e-04 | 175 | 34 | 3 | 1d1cdbf3221b03e24eae38afd57cbd6736b37a53 | |
| ToppCell | NS-moderate-d_07-13-Lymphoid-NK|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 3.17e-04 | 175 | 34 | 3 | f6cd24d22f62469319f9d244e3e5de527d3d4d94 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-24m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.17e-04 | 175 | 34 | 3 | d67c77eee979ad029e7545f383326f0ff77c6e5f | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF1-AF1_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.22e-04 | 176 | 34 | 3 | cb8fd56a4f935cdda19d7ab43382cdda7c307667 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum_-18m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.22e-04 | 176 | 34 | 3 | ef0ff02897104e938c8a632357d8f1a6f014e68a | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum_-18m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.22e-04 | 176 | 34 | 3 | da0983929fa682a68e536c298a2d7add188b7563 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-B_(Myofibroblast)|343B / Donor, Lineage, Cell class and subclass (all cells) | 3.27e-04 | 177 | 34 | 3 | e55d21d4d61a069b9bbe0e7595fbfb7cfbacfd87 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-B_(Myofibroblast)-|343B / Donor, Lineage, Cell class and subclass (all cells) | 3.27e-04 | 177 | 34 | 3 | 43ba6f12c2fb32698a420bf799d46ac1b558f146 | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_NK-T_NK-mature_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.27e-04 | 177 | 34 | 3 | 0f2616a81f8fbede77c860b2126e3fa826672da3 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-E-|356C / Donor, Lineage, Cell class and subclass (all cells) | 3.33e-04 | 178 | 34 | 3 | a493a277d175e5e153410a745b26ebe2e0839ea0 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-E|356C / Donor, Lineage, Cell class and subclass (all cells) | 3.33e-04 | 178 | 34 | 3 | 371218babddfd3d8a7bb82a46ce65327ee3fcf12 | |
| ToppCell | droplet-Spleen-nan-3m-Lymphocytic-immature_NKT_cell|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.38e-04 | 179 | 34 | 3 | 54621d2b3a66e62aa76b7e444118878ed97c1e02 | |
| ToppCell | 3'-GW_trimst-1-LargeIntestine-Hematopoietic-T_cells|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.38e-04 | 179 | 34 | 3 | e717c0079b788a3703c0a450922bd5a2bdc322a0 | |
| ToppCell | facs-Bladder-nan-24m-Epithelial-bladder_mesenchymal_cell_(Car3+)|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.44e-04 | 180 | 34 | 3 | 12537d8a569faa69f474284d2c201475722b8ca1 | |
| ToppCell | MatrixFB-Fibroblast-A|MatrixFB / shred on cell class and cell subclass (v4) | 3.44e-04 | 180 | 34 | 3 | adc64ad6033af705dd7b9163a83e20ef5c59f6eb | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-Tuft-related|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.44e-04 | 180 | 34 | 3 | 8ba9bba0c9fecf184a4332ba4585fb2439f68cd3 | |
| ToppCell | facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.50e-04 | 181 | 34 | 3 | 1037051eb82313c13346617b33f3c4c648181c4d | |
| ToppCell | Children_(3_yrs)-Mesenchymal-pericyte_cell-D139|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.50e-04 | 181 | 34 | 3 | 451b87ac95154bb80018b8dd245b4a6389d81411 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-NK-NK-C|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.50e-04 | 181 | 34 | 3 | a7f0a83e4f48eca8e753bda13c744cf41359fcc0 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_bright-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.50e-04 | 181 | 34 | 3 | 9c4f9abb9335da2b07644bca8faff1baa1bb9f5b | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-Tuft-related-BEST4+_epithelial|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.55e-04 | 182 | 34 | 3 | e98ca9df33a1a81fc83ecf73d5141a14f2bc985c | |
| ToppCell | Smart-start-Cell-Wel_seq-Neoplastic-Differentiated-like-AC-like-AC-like-D|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 3.55e-04 | 182 | 34 | 3 | 209b455eaa135825fa6e6c71bf7d2072cebf11f2 | |
| ToppCell | Adult-Mesenchymal-pericyte_cell-D122|Adult / Lineage, Cell type, age group and donor | 3.61e-04 | 183 | 34 | 3 | fc31a43a637423cb3bb9aa184a3a889a0b9aaea6 | |
| ToppCell | moderate-Lymphoid-NK|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.73e-04 | 185 | 34 | 3 | 4979a787acbc9b4ca8defe91cc79b674e51af1bf | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 3.73e-04 | 185 | 34 | 3 | 9f19f04fc4d97dfc2dd78cde77b515f1cb5d51ec | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_2_cell-D231|Adult / Lineage, Cell type, age group and donor | 3.73e-04 | 185 | 34 | 3 | fb6bd7e849ecf4ed9cd9c4e2a946a2d12d62f804 | |
| ToppCell | COVID-19-Fibroblasts-Adventitial_FB|COVID-19 / group, cell type (main and fine annotations) | 3.73e-04 | 185 | 34 | 3 | a5aebf2b9b05b550d021272731d68af9a6b1229d | |
| ToppCell | Mild-NK|World / Disease group and Cell class | 3.73e-04 | 185 | 34 | 3 | 0565b7c464e1a09e596f5a0b363d2dc9b55c3c50 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_bright-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.79e-04 | 186 | 34 | 3 | 5ad37549592eab23f166196ebf0cb9c8ddf26082 | |
| ToppCell | 10x5'v1-week_12-13-Lymphocytic_NK-T_NK-mature_NK|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 3.79e-04 | 186 | 34 | 3 | 165d02be3b3eaeb8784a2b0b2020928b21a19bc7 | |
| ToppCell | 10x_3'_v3-thymus_(10x_3'_v3)-lymphocytic-innate_lymphocytic-mature_NK_T_cell|thymus_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 3.79e-04 | 186 | 34 | 3 | c984e5729958237b101df96d1c89a236faacded6 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 3.79e-04 | 186 | 34 | 3 | 7def03dd856b765bd3f493288641981c4f7fd26e | |
| ToppCell | Adult-Mesenchymal-pericyte_cell|Adult / Lineage, Cell type, age group and donor | 3.85e-04 | 187 | 34 | 3 | 62759efb660179402fb574ce5701c89a2e17bcfe | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_dim-male|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.85e-04 | 187 | 34 | 3 | 0bca79cea4886b66350c56c61859bd71e1e7a85c | |
| ToppCell | droplet-Heart-4Chambers-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.85e-04 | 187 | 34 | 3 | dba4924d914a7dcd4901142684ba920c2404860b | |
| ToppCell | droplet-Heart-4Chambers-18m-Mesenchymal-smooth_muscle_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.85e-04 | 187 | 34 | 3 | 9688141beef4f62613d7a810c5872ccb9afc1a71 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | a244fcd092d5bd544e503366b1439b0fbc1ee00e | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-3m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | 053c251d3ddbeb866f34565aefca4535517b4387 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-pericyte_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.91e-04 | 188 | 34 | 3 | ee151792c7ac9afe820f1a281c6dab383799f358 | |
| ToppCell | facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | 006db2c2c44971ca9241c582bc89f258c785f5ed | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | 7471c194276161422326647f09022e94f3d1640c | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | c8530c9ff98666c64a94683261af4288cb790a7e | |
| ToppCell | facs-Brain_Non-Myeloid-Hippocampus_-18m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.91e-04 | 188 | 34 | 3 | d0e6fb4a3b3d79d3512b5500062ea285495ae526 | |
| ToppCell | wk_08-11-Hematologic_Lymphocytic-NK-Intermediate_NK|wk_08-11 / Celltypes from embryonic and fetal-stage human lung | 3.91e-04 | 188 | 34 | 3 | a8170e4ce6406af9f5ad5317e6e26efa7bc66411 | |
| ToppCell | 10x3'2.3-week_14-16-Mesenchymal_myocytic-stroma-muscle|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 3.91e-04 | 188 | 34 | 3 | b01cb642f8b2d83235706fec7477c15005094161 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d12-22_no-steroids-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.97e-04 | 189 | 34 | 3 | bed43041e6f8ba19787150a6aaa492f2656135d9 | |
| ToppCell | COVID-19-lung-Secretory|lung / Disease (COVID-19 only), tissue and cell type | 3.97e-04 | 189 | 34 | 3 | 84d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25 | |
| ToppCell | moderate-Lymphoid-NK|Lymphoid / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 3.97e-04 | 189 | 34 | 3 | 22a19365782003c18ec8dddcdbfdaa82c4e330f6 | |
| ToppCell | systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_bright|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 3.97e-04 | 189 | 34 | 3 | 3e148accffc6ab249fb0dff7f3bf5a7fff9da773 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.03e-04 | 190 | 34 | 3 | 9b825b2586c7b173ff27fcf2abc5860faf50984a | |
| ToppCell | nucseq-Mesenchymal-Myocytic-Myocytic_1-Pericyte|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.03e-04 | 190 | 34 | 3 | 4eb92aef1ee868f4537483d19014d947b7684612 | |
| ToppCell | nucseq-Mesenchymal-Myocytic-Myocytic_1|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 4.03e-04 | 190 | 34 | 3 | 7be4341e2909101d756f14031c21e705eb45e69a | |
| ToppCell | 10x5'v1-week_17-19-Lymphocytic_NK-T_NK-CD56_bright_NK|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.03e-04 | 190 | 34 | 3 | 251d50a77e5118a9ad19ea01a7c7c862230ed63c | |
| ToppCell | pdx-Tumor_cells-T1|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 4.03e-04 | 190 | 34 | 3 | d06ee5f89f1cec8db6897fe3b2a890a07cd3697b | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-3m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.03e-04 | 190 | 34 | 3 | d146af1926474328a7c822bc140c4dda66e1bbfb | |
| Drug | Zoxazolamine [61-80-3]; Down 200; 23.8uM; MCF7; HT_HG-U133A | 1.49e-08 | 198 | 34 | 7 | 5390_DN | |
| Drug | Methoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A | 4.15e-07 | 196 | 34 | 6 | 3302_DN | |
| Drug | Levamisole hydrochloride [16595-80-5]; Down 200; 16.6uM; MCF7; HT_HG-U133A | 4.53e-07 | 199 | 34 | 6 | 2257_DN | |
| Drug | Fenbufen [36330-85-5]; Down 200; 15.8uM; PC3; HT_HG-U133A | 9.00e-06 | 191 | 34 | 5 | 4279_DN | |
| Drug | (-)-Isoproterenol hydrochloride [5984-95-2]; Down 200; 16.2uM; MCF7; HT_HG-U133A | 9.71e-06 | 194 | 34 | 5 | 6833_DN | |
| Drug | Talampicillin hydrochloride [39878-70-1]; Up 200; 7.8uM; PC3; HT_HG-U133A | 9.95e-06 | 195 | 34 | 5 | 7254_UP | |
| Drug | Cinoxacin [28657-80-9]; Up 200; 15.2uM; MCF7; HT_HG-U133A | 1.05e-05 | 197 | 34 | 5 | 3463_UP | |
| Drug | Ifosfamide [3778-73-2]; Up 200; 15.4uM; MCF7; HT_HG-U133A | 1.05e-05 | 197 | 34 | 5 | 3485_UP | |
| Drug | Carbinoxamine maleate salt [3505-38-2]; Up 200; 9.8uM; HL60; HT_HG-U133A | 1.07e-05 | 198 | 34 | 5 | 2725_UP | |
| Drug | retinoic acid; Down 200; 1uM; PC3; HT_HG-U133A | 1.07e-05 | 198 | 34 | 5 | 4435_DN | |
| Drug | Minoxidil [38304-91-5]; Down 200; 19.2uM; MCF7; HT_HG-U133A | 1.07e-05 | 198 | 34 | 5 | 4800_DN | |
| Drug | 2-Aminobenzenesulfonamide [3306-62-5]; Down 200; 23.2uM; MCF7; HT_HG-U133A | 1.07e-05 | 198 | 34 | 5 | 5422_DN | |
| Drug | Chlorpropamide [94-20-2]; Up 200; 14.4uM; PC3; HT_HG-U133A | 1.07e-05 | 198 | 34 | 5 | 6291_UP | |
| Drug | Lycorine hydrochloride [2188-68-3]; Down 200; 12.4uM; MCF7; HT_HG-U133A | 1.10e-05 | 199 | 34 | 5 | 3891_DN | |
| Drug | Ethoxyquin [91-53-2]; Up 200; 18.4uM; PC3; HT_HG-U133A | 1.10e-05 | 199 | 34 | 5 | 3764_UP | |
| Drug | Mometasone furoate [83919-23-7]; Down 200; 7.6uM; PC3; HT_HG-U133A | 1.72e-04 | 188 | 34 | 4 | 5116_DN | |
| Drug | Fluticasone propionate [80474-14-2]; Down 200; 8uM; HL60; HT_HG-U133A | 1.76e-04 | 189 | 34 | 4 | 2928_DN | |
| Drug | Astemizole [68844-77-9]; Down 200; 8.8uM; MCF7; HT_HG-U133A | 1.79e-04 | 190 | 34 | 4 | 6807_DN | |
| Drug | Gabazine [105538-73-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A | 1.79e-04 | 190 | 34 | 4 | 3253_DN | |
| Drug | Pempidine tartrate [546-48-5]; Down 200; 13uM; MCF7; HT_HG-U133A | 1.83e-04 | 191 | 34 | 4 | 3926_DN | |
| Drug | Methimazole [60-56-0]; Down 200; 35uM; PC3; HT_HG-U133A | 1.83e-04 | 191 | 34 | 4 | 3815_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; HL60; HT_HG-U133A | 1.86e-04 | 192 | 34 | 4 | 2450_DN | |
| Drug | Fluticasone propionate [80474-14-2]; Down 200; 8uM; MCF7; HT_HG-U133A | 1.90e-04 | 193 | 34 | 4 | 4129_DN | |
| Drug | Ethacrynic acid [58-54-8]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 1.90e-04 | 193 | 34 | 4 | 3181_DN | |
| Drug | Myosmine [532-12-7]; Down 200; 27.4uM; MCF7; HT_HG-U133A | 1.90e-04 | 193 | 34 | 4 | 3634_DN | |
| Drug | Serotonin hydrochloride [153-98-0]; Down 200; 18.8uM; MCF7; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 5268_DN | |
| Drug | Minocycline hydrochloride [13614-98-7]; Up 200; 8uM; PC3; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 5077_UP | |
| Drug | Scopoletin [92-61-5]; Up 200; 20.8uM; MCF7; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 6510_UP | |
| Drug | Gabexate mesilate [56974-61-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 4804_DN | |
| Drug | Omeprazole [73590-58-6]; Down 200; 11.6uM; HL60; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 2467_DN | |
| Drug | Ivermectin [70288-86-7]; Down 200; 4.6uM; MCF7; HT_HG-U133A | 1.94e-04 | 194 | 34 | 4 | 2213_DN | |
| Drug | DFC-28 | 1.95e-04 | 14 | 34 | 2 | CID005743054 | |
| Drug | (R)-Propranolol hydrochloride [13071-11-9]; Down 200; 13.6uM; PC3; HT_HG-U133A | 1.98e-04 | 195 | 34 | 4 | 5814_DN | |
| Drug | Chlorhexidine [55-56-1]; Down 200; 8uM; PC3; HG-U133A | 1.98e-04 | 195 | 34 | 4 | 1942_DN | |
| Drug | Quinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 1.98e-04 | 195 | 34 | 4 | 3191_DN | |
| Drug | Azapropazone [13539-59-8]; Down 200; 13.4uM; MCF7; HT_HG-U133A | 1.98e-04 | 195 | 34 | 4 | 6522_DN | |
| Drug | Idoxuridine [54-42-2]; Down 200; 11.2uM; PC3; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 4200_DN | |
| Drug | Oleandomycin phosphate [7060-74-4]; Down 200; 5uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 5676_DN | |
| Drug | Fusaric acid [536-69-6]; Up 200; 22.4uM; PC3; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 3986_UP | |
| Drug | Morantel tartrate [26155-31-7]; Up 200; 10.8uM; HL60; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 1840_UP | |
| Drug | Propafenone hydrochloride [34183-22-7]; Up 200; 10.6uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 2871_UP | |
| Drug | Harmane hydrochloride [21655-84-5]; Down 200; 18.2uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 4408_DN | |
| Drug | Aspartic acid, N-acetyl (R,S) [997-55-7]; Down 200; 22.8uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 4125_DN | |
| Drug | Ethamsylate [2624-44-4]; Up 200; 15.2uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 7335_UP | |
| Drug | Hymecromone [90-33-5]; Up 200; 22.8uM; PC3; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 4623_UP | |
| Drug | Dobutamine hydrochloride [49745-95-1]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 5386_DN | |
| Drug | Flupentixol dihydrochloride cis-(Z) [2413-38-9]; Down 200; 7.8uM; PC3; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 6708_DN | |
| Drug | Heptaminol hydrochloride [543-15-7]; Down 200; 22uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 6015_DN | |
| Drug | Pivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; MCF7; HT_HG-U133A | 2.02e-04 | 196 | 34 | 4 | 6014_DN | |
| Drug | Nizatidine [76963-41-2]; Down 200; 12uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 5406_DN | |
| Drug | Diphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; HL60; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 2205_DN | |
| Drug | Prochlorperazine dimaleate [84-02-6]; Up 200; 6.6uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 2641_UP | |
| Drug | Methiazole; Down 200; 15uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 4532_DN | |
| Drug | 0317956-0000 [391210-11-0]; Down 200; 1uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 3777_DN | |
| Drug | Dropropizine (R,S) [17692-31-8]; Up 200; 17uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 5106_UP | |
| Drug | U-62066 [87151-85-7]; Down 200; 1uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 3818_DN | |
| Drug | Sulfamonomethoxine [1220-83-3]; Up 200; 14.2uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 5843_UP | |
| Drug | Flunarizine dihydrochloride [30484-77-6]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 7412_UP | |
| Drug | Procyclidine hydrochloride [1508-76-5]; Down 200; 12.4uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 4233_DN | |
| Drug | Pargyline hydrochloride [306-07-0]; Down 200; 20.4uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 2265_DN | |
| Drug | Piromidic acid [19562-30-2]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 3335_DN | |
| Drug | Proxyphylline [603-00-9]; Down 200; 16.8uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 5993_DN | |
| Drug | Podophyllotoxin [518-28-5]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 6103_DN | |
| Drug | Vitamin K2 [11032-49-8]; Down 200; 9uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 3798_DN | |
| Drug | Hyoscyamine (L) [101-31-5]; Up 200; 13.8uM; PC3; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 5099_UP | |
| Drug | Naringenine [480-41-1]; Down 200; 14.6uM; HL60; HT_HG-U133A | 2.06e-04 | 197 | 34 | 4 | 1342_DN | |
| Drug | Nifenazone [2139-47-1]; Down 200; 13uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 6016_DN | |
| Drug | Dexamethasone acetate [1177-87-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2242_DN | |
| Drug | Zoxazolamine [61-80-3]; Up 200; 23.8uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 6290_UP | |
| Drug | Chlortetracycline hydrochloride [64-72-2]; Up 200; 7.8uM; HL60; HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2042_UP | |
| Drug | Ornidazole [16773-42-5]; Down 200; 18.2uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2272_DN | |
| Drug | Vitamin K2 [11032-49-8]; Down 200; 9uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 3880_DN | |
| Drug | Evoxine [522-11-2]; Down 200; 11.6uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 3681_DN | |
| Drug | (1-[(4-Chlorophenyl)phenyl-methyl]-4-methylpiperazine) [1620-21-9]; Up 200; 11.8uM; HL60; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2197_UP | |
| Drug | Quinidine hydrochloride monohydrate [6151-40-2]; Down 200; 10.6uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 5793_DN | |
| Drug | Biperiden hydrochloride [1235-82-1]; Up 200; 11.4uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 5644_UP | |
| Drug | Oleandomycin phosphate [7060-74-4]; Up 200; 5uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4615_UP | |
| Drug | Brompheniramine maleate [980-71-2]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4131_DN | |
| Drug | Succinylsulfathiazole [116-43-8]; Down 200; 11.2uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2821_DN | |
| Drug | Hippeastrine hydrobromide [22352-41-6]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 6042_DN | |
| Drug | 3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 5259_DN | |
| Drug | PHA-00851261E [724719-49-7]; Up 200; 1uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4333_UP | |
| Drug | Mephenytoin [50-12-4]; Down 200; 18.4uM; HL60; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 6158_DN | |
| Drug | nordihydroguaiaretic acid; Down 200; 1uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 5583_DN | |
| Drug | Triamterene [396-01-0]; Down 200; 15.8uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 7307_DN | |
| Drug | Pepstatin A [26305-03-3]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 3264_DN | |
| Drug | Tadjakonine [11087-94-8]; Up 200; 7.4uM; HL60; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2165_UP | |
| Drug | Pentylenetetrazole [54-95-5]; Up 200; 29uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2255_UP | |
| Drug | Cefadroxil [50370-12-2]; Down 200; 11uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4080_DN | |
| Drug | Bacampicillin hydrochloride [37661-08-8]; Down 200; 8uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4592_DN | |
| Drug | Ioversol [87771-40-2]; Up 200; 5uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 5326_UP | |
| Drug | Eucatropine hydrochloride [536-93-6]; Up 200; 12.2uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 4316_UP | |
| Drug | Fendiline hydrochloride [13636-18-5]; Down 200; 11.4uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 3190_DN | |
| Drug | 11-deoxy-16,16-dimethyl Prostaglandin E2; Down 200; 10uM; PC3; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 7519_DN | |
| Drug | estradiol, USP; Down 200; 0.01uM; MCF7; HG-U133A | 2.10e-04 | 198 | 34 | 4 | 121_DN | |
| Drug | Dacarbazine [4342-03-4]; Up 200; 22uM; MCF7; HT_HG-U133A | 2.10e-04 | 198 | 34 | 4 | 2754_UP | |
| Drug | Quinic acid [86-68-0]; Up 200; 19.6uM; HL60; HT_HG-U133A | 2.14e-04 | 199 | 34 | 4 | 2978_UP | |
| Drug | Griseofulvin [126-07-8]; Down 200; 11.2uM; PC3; HT_HG-U133A | 2.14e-04 | 199 | 34 | 4 | 3664_DN | |
| Drug | Adamantamine fumarate [80789-67-9]; Down 200; 9.6uM; MCF7; HT_HG-U133A | 2.14e-04 | 199 | 34 | 4 | 4806_DN | |
| Drug | S(-)Eticlopride hydrochloride [97612-24-3]; Down 200; 10.6uM; MCF7; HT_HG-U133A | 2.14e-04 | 199 | 34 | 4 | 5695_DN | |
| Disease | Malignant neoplasm of urinary bladder | 1.62e-05 | 141 | 32 | 4 | C0005684 | |
| Disease | conotruncal heart malformations | 2.57e-04 | 114 | 32 | 3 | MONDO_0016581 | |
| Disease | Bladder Neoplasm | 4.69e-04 | 140 | 32 | 3 | C0005695 | |
| Disease | squamous cell lung carcinoma | 7.56e-04 | 165 | 32 | 3 | EFO_0000708 | |
| Disease | cortical thickness | 1.11e-03 | 1113 | 32 | 6 | EFO_0004840 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| RLTSLPPKGGTSNGY | 26 | Q9UMD9 | |
| TSSTLLPYGIKSLPL | 541 | O95936 | |
| TLRLPSLSGSDGIPY | 901 | P21709 | |
| TGTLGLPYLRGTSRP | 151 | Q6UVK1 | |
| STLERGYPKPLTSLG | 546 | P08253 | |
| VAYSPRSKLGTLLPE | 166 | Q33E94 | |
| GYTLSLPAVSPGKRL | 151 | Q8TD91 | |
| YPSLLRTPSAGGLKA | 781 | Q8IV33 | |
| DPTYTSSLGGKIPIR | 771 | P54760 | |
| TIPGGLYPSKSIILS | 231 | Q6DKI2 | |
| TLTTEGPSTPRLYIG | 146 | Q76MJ5 | |
| TIPGGLYPSKSIILS | 231 | Q3B8N2 | |
| PFITTILGGLYPSKS | 226 | O00182 | |
| YPSKSILLSGTVLPS | 236 | O00182 | |
| PGSSFSKLLLPYREG | 101 | O60486 | |
| RIILSGPSGTGKTYL | 2051 | Q8IVL0 | |
| SPTLVKNIPTSLGYG | 591 | O15409 | |
| SGLLSTTYLPRKPQA | 736 | Q6ZVL6 | |
| FLKGPSPRLTYLSVA | 146 | Q5SZD4 | |
| GLRSKTLRGTPNYLP | 46 | P09565 | |
| QPGSLYLAKTSTLPR | 2506 | P51587 | |
| PYPTLSTPLSKRTSG | 16 | P55285 | |
| LTTLTTGRKGSYPLP | 466 | P54803 | |
| SRSLPSSPLRLGSYK | 351 | O14830 | |
| GNSALLSLPGYRPTT | 1866 | Q14980 | |
| IITGYPTPGSKLSLR | 796 | A6NKG5 | |
| YLLKRILGSLPPTGT | 236 | Q9H611 | |
| LLLYGPPGTGKTSTI | 56 | P40937 | |
| KVYSLPLSLTPTGQG | 676 | O14594 | |
| LTPITGAKPSATGYL | 1336 | O95785 | |
| LKEPGALPSTYRSLV | 1226 | Q99973 | |
| LFIYTSGTTGLPKPA | 291 | Q9Y2P5 | |
| RPKQPLLSSGLYSSG | 301 | Q5T1R4 | |
| GTTLSLPPYSLERKL | 256 | C9JH25 | |
| SLTGGRPFPKTTSTL | 896 | Q86UU1 | |
| KTSLRTLPTGYRLPG | 4951 | P20929 |